[Efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer: A meta-analysis].

ABSTRACT

OBJECTIVE: To evaluate the clinical efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: We searched PubMed, Medline, Embase, Cochrane Library, CNKI, VIP, CBM and Wanfang Database from inception to July 2019 for published retrospective studies on the treatment of mCRPC. We performed literature screening, data extraction and quality evaluation according to the inclusion and exclusion criteria, and conducted a meta-analysis of the data obtained using the STATA15.1 software. RESULTS: A total of 12 studies involving 508 cases of mCRPC were included in this analysis. After the first cycle of treatment, the pooled rate of PSA decline was 69.30% (95% CI 65.40%－73.30%), and that of >50% PSA decline was 35.90% (95% CI 31.80%－40.00%). No significant adverse events were reported in any of the studies. CONCLUSIONS: The177Lu-PSMA-617 therapy is a safe and effective option for the treatment of metastatic castration-resistant prostate cancer.